TY - JOUR
T1 - Safety of the extension of use of galacto-oligosaccharides as a novel food pursuant to Regulation (EU) 2015/2283
AU - Turck, Dominique
AU - Bohn, Torsten
AU - Cámara, Montaña
AU - Castenmiller, Jacqueline
AU - De Henauw, Stefaan
AU - Jos, Ángeles
AU - Maciuk, Alexandre
AU - Mangelsdorf, Inge
AU - McNulty, Breige
AU - Naska, Androniki
AU - Pentieva, Kristina
AU - Siani, Alfonso
AU - Thies, Frank
AU - Aguilera-Gómez, Margarita
AU - Frenzel, Thomas
AU - McArdle, Harry J.
AU - Moldeus, Peter
AU - Neuhäuser-Berthold, Monika
AU - Schlatter, Josef Rudolf
AU - van Loveren, Henk
AU - Turla, Emanuela
AU - Azzollini, Domenico
AU - Hirsch-Ernst, Karen Ildico
AU - EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA)
N1 - © 2025 European Food Safety Authority. EFSA Journal published by Wiley‐VCH GmbH on behalf of European Food Safety Authority.
PY - 2025/12/16
Y1 - 2025/12/16
N2 - Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the extension of use of galacto-oligosaccharides (GOS) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is produced from milk-derived lactose using β-galactosidases. The applicant proposed to extend the use of GOS to several food categories (non-alcoholic beverages, confectionery, chewing gum, cocoa and chocolate-based products and protein products). The target population is the general population. GOS is already authorised and included in the Union list of NFs for use in several foods, including infant formula, and in food supplements. The Panel estimated that the proposed extension of use would result in a highest 95th percentile intake of GOS from all food uses, of up to 48.5 g/day in adults. As compared to the exposure to GOS from the currently authorised food uses (at the highest P95), the proposed extension of use is expected to result in an increase in intake of GOS of up to 17%. The information provided on the proposed use levels and anticipated intake does not raise safety concerns. The Panel concludes that the proposed extension of use of GOS is safe under the proposed conditions of use.
AB - Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the extension of use of galacto-oligosaccharides (GOS) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is produced from milk-derived lactose using β-galactosidases. The applicant proposed to extend the use of GOS to several food categories (non-alcoholic beverages, confectionery, chewing gum, cocoa and chocolate-based products and protein products). The target population is the general population. GOS is already authorised and included in the Union list of NFs for use in several foods, including infant formula, and in food supplements. The Panel estimated that the proposed extension of use would result in a highest 95th percentile intake of GOS from all food uses, of up to 48.5 g/day in adults. As compared to the exposure to GOS from the currently authorised food uses (at the highest P95), the proposed extension of use is expected to result in an increase in intake of GOS of up to 17%. The information provided on the proposed use levels and anticipated intake does not raise safety concerns. The Panel concludes that the proposed extension of use of GOS is safe under the proposed conditions of use.
KW - GOS
KW - extension of use
KW - galacto-oligosaccharides
KW - novel food
UR - https://www.scopus.com/pages/publications/105025144116
UR - https://pubmed.ncbi.nlm.nih.gov/41409114/
U2 - 10.2903/j.efsa.2025.9797
DO - 10.2903/j.efsa.2025.9797
M3 - Article
C2 - 41409114
AN - SCOPUS:105025144116
SN - 1831-4732
VL - 23
JO - EFSA Journal
JF - EFSA Journal
IS - 12
M1 - e9797
ER -